Quinise 300 Tablet
Quinine Sulphate
200mg
G.D. Laboratories Pvt. Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Indications
Quinise 300 Tablet is used for:
Malaria, Nocturnal leg cramps
Adult Dose
Oral
Malaria
Adult: As sulfate: 648 mg 8 hrly for 7 days.
Nocturnal leg cramps
Adult: 200-300 mg once at night.
Hepatic impairment: Mild to moderate (Child-Pugh class A and B): No dosage adjustment needed.
Child Dose
Oral
Malaria
Child: As sulfate: >8 yr10 mg/kg 8 hrly for 7 days.
Renal Dose
Renal impairment: Severe: Initially, 648 mg followed after 12 hr by maintenance doses of 324 mg 12 hrly.
Administration
Should be taken with food. Take w/ food to minimise GI discomfort.
Contra Indications
Hypersensitivity to quinine, mefloquine or quinidine. Patients w/ nocturnal leg cramps; prolonged QT interval, tinnitus or optic neuritis, myasthenia gravis, G6PD deficiency, haemolysis and who had suffered from black water fever. Concomitant use w/ ritonavir, mefloquine, rifampicin, class IA and class III antiarrhythmic agents, neuromuscular blocking agents, other drugs known to cause QT prolongation, and Al- and/or Mg-containing antacids.
Precautions
Patients w/ cardiac conduction defects, heart block or AF. Pregnancy and lactation. Monitoring Parameters Monitor for signs of cardiotoxicity. Monitor blood glucose levels, CBC w/ platelet count, LFT, ECG; ophthalmologic exam.
Pregnancy-Lactation
Interactions
Reduced renal clearance of amantadine. Reduced clearance w/ cimetidine. Increased anticoagulant effect of warfarin and other anticoagulants. Reduced plasma levels of ciclosporin. Increased plasma levels of digoxin. Increased risk of myopathy and rhabdomyolysis w/ atorvastatin. May enhance hypoglycaemic effects of oral antidiabetics.
Potentially Fatal: Increased risk of QT prolongation and torsade de pointes w/ mefloquine, class IA antiarrhythmic agents (e.g. quinidine, procainamide, disopyramide) and class III antiarrhythmic agents (e.g. amiodarone, sotalol, dofetilide) and other drugs known to cause QT prolongation (e.g. halofantrine, pimozide, thioridazine). Potentiates neuromuscular blockade w/ neuromascular blocking agents. Decreased plasma levels w/ rifampicin. Increased serum levels w/ ritonavir. May delay or decrease absorption w/ Al- and/or Mg-containing antacids.
Adverse Effects
Side effects of Quinine Sulphate :
<1%
Flushing of the skin,Anginal symptoms,Fever,Rash,Pruritus,Hypoglycemia,Epigastric pain,Hemolysis in G6PD deficiency,Thrombocytopenia,Hepatitis,Nightblindness,Diplopia,Optic atrophy,Impaired hearing,Hypersensitivity reaction
Frequency Not Defined
Severe headache,Nausea,Vomiting,Diarrhea,Blurred vision,Tinnituscinchonism (risk of cinchonism is directly related to dose and duration of therapy)
Potentially Fatal: Sinus arrest, AV block, ventricular fibrillation and sudden death especially with IV use.
Mechanism of Action
Quinine is a cinchona alkaloid and a 4-methanolquinoline. It rapidly acts on blood schizontocide by interfering w/ lysosomal function or nucleic acid synthesis in the Plasmodia spp. It has no activity against exoerythrocytic forms.
Note
Quinise 300 200mg Tablet manufactured by G.D. Laboratories Pvt. Ltd.. Its generic name is Quinine Sulphate. Quinise 300 is availble in Nepal.
Farmaco Nepal drug index information on Quinise 300 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.